NVST stock sentiment todayEnvista Holdings Corporation
Sentiment verdict
Gossip first, financials second — COLD at 65% confidence.
Last updated · cached analysis, refreshes periodically
NVST
Envista Holdings CorporationA dental laggard struggling with operational execution and management turnover in a sluggish high-end equipment market.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for NVST. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by a 'show-me' story following a CEO transition and consistent earnings misses. Investors are frustrated by the slow recovery in the specialty dental segment (implants) and the loss of market share to nimbler competitors.
- ·Recent leadership changes (Paul Keel appointment)
- ·Persistent weakness in the Spark aligner and Nobel Biocare implant segments
- ·Restructuring and cost-saving initiatives not yet hitting the bottom line
Financial
Financials are pressured by contracting margins and stagnant organic growth. While the balance sheet isn't in immediate distress, FCF generation has been disappointing compared to historical Danaher-spin-off expectations.
- ·Negative organic sales growth in recent quarters
- ·EBITDA margins compressed from 20% range to mid-teens
- ·P/E ratio appears low but is skewed by downward earnings revisions
- ·Net Debt/EBITDA leverage currently elevated due to earnings contraction
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Further market share loss in premium implants to Straumann
- ·High sensitivity to consumer discretionary spending for orthodontic procedures
- ·Execution risk regarding the ongoing portfolio optimization and site consolidations
Peer temperature
How direct competitors stack up against NVST right now.
- HOTSTMNStraumann Holding AG
HOTTER — Dominating the premium implant market with superior R&D and consistently higher organic growth rates.
See full analysis → - NEUTRALDENTSPLYDentsply Sirona Inc.
WARMER — Also facing turnaround hurdles, but possesses a more diversified global footprint and better equipment replacement cycle visibility.
See full analysis → - NEUTRALALGNAlign Technology, Inc.
WARMER — High volatility, but maintains a massive ecosystem moat in clear aligners that Envista's 'Spark' has failed to meaningfully disrupt.
See full analysis →
- NVST-4.7%
- STMN—
- DENTSPLY—
- ALGN-9.3%
Analyst price target
Consensus average of 11 analysts · median 32.00
Source: StockAnalysis.com · updated 2026-09-03
AI-generated analysis for informational purposes only. Not financial advice.